Finance

Beta
Lists
GBT:EPA
Guerbet SA
€10.36
+0.19%
(+0.020) 1D
Jun 3, 5:35:03 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GBT...
Open
€10.34
High
€10.38
Low
€10.14
Mkt. cap
127.43M
Avg. vol.
14.94K
Volume
12.68K
52-wk high
€23.70
52-wk low
€8.01
EPS
-€8.57
Shares outstanding
12.64M
No. of employees
3K
Open
€10.34
High
€10.38
Low
€10.14
Mkt. cap
127.43M
Avg. vol.
14.94K
Volume
12.68K
52-wk high
€23.70
52-wk low
€8.01
EPS
-€8.57
Shares outstanding
12.64M
No. of employees
3K
News stories
From sources across the web
Profile
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent. In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index. In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015. In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories. An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
About Guerbet SA
CEODavid Hale
Employees2.7K
Founded1926
Headquarters-
SectorMedical device
Last report
Apr 23, 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
177.40M / 141.80M
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
197.36M
197.36M
201.97M
201.97M
Cost of goods sold
40.26M
40.26M
70.76M
70.76M
Cost of revenue
40.26M
40.26M
70.76M
70.76M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
129.34M
129.34M
105.69M
105.69M
Operating expense
149.62M
149.62M
134.65M
134.65M
Total operating expenses
189.88M
189.88M
205.41M
205.41M
Operating income
7.48M
7.48M
-3.44M
-3.44M
Other non operating income
-1.12M
-1.12M
649.00K
649.00K
EBT including unusual items
1.32M
1.32M
-56.11M
-56.11M
EBT excluding unusual items
1.32M
1.32M
-7.98M
-7.98M
Income tax expense
672.50K
672.50K
865.50K
865.50K
Effective tax rate
50.97%
50.97%
-1.54%
-1.54%
Other operating expenses
5.56M
5.56M
13.25M
13.25M
Net income
1.32M
1.32M
-55.48M
-55.48M
Net profit margin
0.67%
0.67%
-27.47%
-27.47%
Earnings per share
-
-
-
-
Interest and investment income
75.00K
75.00K
110.50K
110.50K
Interest expense
-5.04M
-5.04M
-4.87M
-4.87M
Net interest expenses
-4.96M
-4.96M
-4.76M
-4.76M
Depreciation and amortization charges
14.72M
14.72M
15.71M
15.71M
EBITDA
22.20M
22.20M
788.50K
788.50K
Gain or loss from assets sale
-76.50K
-76.50K
3.52M
3.52M
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more